BioSpace News Archive

VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on June 18, 2020 (the “Meeting”).

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA Securities Napa Biopharma Conference on Wednesday, June 24, 2020 at 3:30 PM EDT / 12:30 PM PDT.

Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical”) today announced that the Company is set to join the broad market Russell 3000® Index, the Russell 2000® Index, and Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution,

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.

Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company focused on developing novel medicines for autoimmune and inflammatory diseases, today announced dosing of the first patient in their Phase II, global clinical trial (RSJ10521) of SHR0302,

Patterson Companies announced that it will hold its fiscal 2020 fourth-quarter and year end conference call on Wednesday, June 24, 2020 at 9 a.m. CT.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the pricing of its initial public offering of 13,882,352 shares of common stock at a public offering price of $20.00 per share.

American Medical Technologies (“AMT”) has become aware of a data security incident that may have involved the personal information of certain AMT customers.

Repare Therapeutics Inc., a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, announced the pricing of its upsized initial public offering of 11,000,000 of its common shares at a public offering price of $20.00 per share.